<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>oncology diagnostics &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/oncology-diagnostics/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 20:30:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>oncology diagnostics &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Biomarkers in Anti-TIF1-γ Dermatomyositis Cancer Risk</title>
		<link>https://bioengineer.org/new-biomarkers-in-anti-tif1-%ce%b3-dermatomyositis-cancer-risk/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 20:29:53 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[**Etiketler:** anti-TIF1-γ dermatomyositis]]></category>
		<category><![CDATA[and novel biomarkers for stratification]]></category>
		<category><![CDATA[anti-TIF1-γ]]></category>
		<category><![CDATA[autoimmune disease oncology]]></category>
		<category><![CDATA[Based on the content focusing on the link between anti-TIF1-γ dermatomyositis]]></category>
		<category><![CDATA[biomarker validation **Açıklama:** 1. **anti-TIF1-γ dermatomyositis**: Makalenin ana odağı olan spesifik otoimmün hastalık. 2. **cancer risk biomarkers**: Yeni biyobelirteçlerin kanser riskini öngör]]></category>
		<category><![CDATA[Cancer risk]]></category>
		<category><![CDATA[cancer risk biomarkers]]></category>
		<category><![CDATA[cancer screening protocols]]></category>
		<category><![CDATA[dermatooncology** **Explanation:** 1. **dermatomyositis:** The core autoimmune disease being studied. 2. **anti-TIF1-γ:** The specific autoantibody]]></category>
		<category><![CDATA[here are 5 appropriate tags: **dermatomyositis]]></category>
		<category><![CDATA[oncology diagnostics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-biomarkers-in-anti-tif1-%ce%b3-dermatomyositis-cancer-risk/</guid>

					<description><![CDATA[In a recent illuminating study, Koumprentziotis et al. delve into the intersection of dermatology and oncology by exploring the connection between anti-TIF1-γ-positive dermatomyositis and cancer risk. This groundbreaking research sheds light on novel biomarkers that could revolutionize how medical professionals approach the stratification of cancer risk in patients with this specific autoimmune condition. The significance [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320452</post-id>	</item>
	</channel>
</rss>
